Disclosure: This site may earn affiliate commissions when you click provider links. This doesn't affect our recommendations. Learn more
GLP-1 microdosing explained: what the evidence shows, the real dosing risks, and what Noom Med, Shed, Enhance.MD, and Hims/Hers charge for microdose plans.
GLP-1 microdosing went from a TikTok trend to a product category in about a year. Telehealth companies now sell named "microdose" plans, and plenty of patients are already doing it on their own. One 2025 poll of 640 GLP-1 users found 36% said they were currently microdosing (Tebra, 2025). A much larger survey put the figure lower, at 9.3% of current injectable users (ISPOR 2026 abstract, Evidation Health). Either way, it's common. The problem is that the evidence hasn't caught up with the marketing. This guide covers what microdosing actually means, what the research does and doesn't show, where the real risks are, and what the providers with named microdose plans charge. GLP-1 medications require a prescription, so any of this starts with a licensed provider.
Answer 10 questions and get a personalized recommendation.
Take the free quiz →There's no clinical definition. In practice, it means taking semaglutide or tirzepatide below the FDA-approved maintenance dose, usually by staying at or near the starting dose for months instead of stepping up.
Compare that to the labels. Wegovy injections start at 0.25 mg weekly and step up every four weeks through 0.5 mg, 1 mg, and 1.7 mg before reaching a maintenance dose of 1.7 mg or 2.4 mg (Wegovy prescribing information, DailyMed). Zepbound starts at 2.5 mg, and Lilly's medical information says plainly that "the 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage" (Lilly Medical).
So what do the commercial plans look like against that? Enhance.MD's microdose tirzepatide is 1 mg per week, which is below Zepbound's 2.5 mg starting dose. Hims and Hers' Wegovy Pill Microdosing Plan starts at 1.5 mg and holds at 4 mg (Hims website, October 2026), the first two steps toward the pill's 25 mg dose (Novo Nordisk announcement). Noom Med doesn't publish its microdose amounts; it says only that the program uses lower doses than its standard plan. None of these is the full maintenance dose the trials studied.
Survey data points to three reasons. In the Evidation Health survey of more than 75,000 respondents, microdosers cited managing side effects (40.8%), cutting costs (31.9%), and supporting weight maintenance (29.6%) (ISPOR 2026 abstract).
Side effects. The labels themselves escalate slowly "to reduce the risk of gastrointestinal adverse reactions," and the Wegovy label tells prescribers to consider delaying escalation if a dose isn't tolerated (DailyMed). Microdosing stretches that logic out indefinitely. If nausea is your issue, our GLP-1 side effects guide covers management options first.
Cost. Less drug can mean a lower bill, especially with compounded vials. At several providers, the microdose plan is the lowest-priced tier.
Maintenance. Some people reach their goal and want to taper rather than stop cold. If that's you, read our guide on stopping GLP-1s and weight regain before deciding.
Here's the part that should give you pause. Both surveys found that social media was a leading source of microdosing information (Evidation, 2025; Tebra, 2025). In the Tebra poll, 55% of microdosers said they made the decision without consulting their doctor (Tebra, 2025).
The honest answer: almost nothing has tested microdosing directly.
The weight-loss figures you see quoted for semaglutide and tirzepatide come from trials of full maintenance doses. In SURMOUNT-1, the lowest tirzepatide maintenance dose (5 mg) produced a mean 15.0% weight reduction at 72 weeks, versus 20.9% at 15 mg and 3.1% on placebo (NEJM, 2022). That's a dose-response pattern. And 5 mg is still five times the 1 mg weekly dose in Enhance.MD's microdose tirzepatide plan, so you can't read that 15% onto a microdose.
A 2026 narrative review in Cureus concluded that studies on GLP-1 microdosing are extremely limited and that the established benefits of standard doses can't be assumed to carry over to fractional dosing (Cureus, 2026). The same review noted that trials specifically designed to test a microdosing strategy are still missing.
Some clinics pitch microdosing as an anti-aging or anti-inflammatory protocol. The cardiovascular benefits linked to GLP-1s were seen in trials at standard doses, such as the SELECT cardiovascular outcomes trial of semaglutide 2.4 mg (NEJM, 2023). There's no trial showing a microdose delivers them. If you're curious about those broader effects, our piece on GLP-1 hidden benefits covers what the full-dose research found.
Pros
Cons
Most microdose plans ship compounded semaglutide or tirzepatide in multi-dose vials. You draw your own dose with a syringe. The smaller the dose, the smaller the margin for error.
The FDA has received "multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors associated with compounded injectable semaglutide products" (FDA). The agency says the errors came from patients measuring and self-administering incorrect doses and, in some cases, health care professionals miscalculating doses. It also stresses that compounded drugs are not FDA-approved, meaning the agency does not review them for safety, effectiveness, or quality before they're sold.
Before you start, confirm three things with your prescriber: the drug concentration on your vial, the exact volume or syringe units for your dose, and what to do if the concentration changes on a refill. For more on the compounded supply chain, see is compounded semaglutide safe?
The FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage resolved on February 21, 2025. The grace periods for compounders ended in 2025, including May 22, 2025 for semaglutide outsourcing facilities (FDA). Some telehealth providers continue to offer compounded GLP-1s, which the FDA says may only be compounded under limited circumstances now that the shortages have ended (FDA), and regulatory pressure on the category is a real risk for anyone planning months of treatment. Our compounded vs. brand-name semaglutide guide explains the trade-offs.
Five providers in our database sell a plan labeled "microdose" (Hims and Hers share one plan). Prices were checked against each provider's website in October 2026 (see our October 2026 pricing check) and may change; confirm current pricing before you sign up. Noom Med's microdose page lists both compounded semaglutide and tirzepatide under the same $79 start and $179/month pricing, noting that final pricing depends on program selection.
| Provider | Plan | Medication | Monthly cost | Fine print |
|---|---|---|---|---|
| Noom Med | GLP-1 Microdose Program | Compounded semaglutide or tirzepatide (dose not published) | $179/mo all-inclusive | Billed quarterly; first 4 weeks $79 (limited time); final price depends on program selection |
| Shed | Microdose | Compounded semaglutide | From $149/mo | 2-month minimum |
| Shed | Microdose | Compounded tirzepatide | From $199/mo | 2-month minimum |
| Enhance.MD | Microdose Tirzepatide | Compounded tirzepatide, 1 mg/week | $169/mo (12-month plan); $199 month to month | Includes labs; ships every 12 weeks |
| Hims / Hers | Wegovy Pill Microdosing Plan | Brand Wegovy pill, 1.5 mg then 4 mg | From $149/mo + $149/mo membership | Membership is $39 the first month |
Sources: Noom Med website, October 2026; Shed website, October 2026; Enhance.MD website, October 2026; Hims website, October 2026; Hers website, October 2026.
Cheapest headline price: Shed's microdose semaglutide at $149/month. Expect a two-month commitment.
Most structured program: Noom Med bundles medication, coaching, and its behavior-change app at $179/month, and it's the only plan here offering either semaglutide or tirzepatide. Note the quarterly billing, and ask what dose you'll get, since Noom doesn't publish it.
Tirzepatide on a budget: Enhance.MD's $169/month requires a 12-month plan; month to month it's $199, the same as Shed's microdose tirzepatide, which needs only a 2-month commitment. Enhance.MD includes lab testing but isn't available in every state.
Brand-name only: Hims and Hers are the only options here using an FDA-approved product, the Wegovy pill (Novo Nordisk announcement). The catch is the membership. That's $298/month at the 1.5 mg starting dose and $348/month at the 4 mg step, based on Novo's $199/month self-pay price for 4 mg, so roughly double the compounded plans.
Shed
Microdose from $149/mo
Microdose compounded semaglutide ($149/mo) or tirzepatide ($199/mo), no membership fee.
Noom Med
$179/mo, first 4 weeks $79
All-inclusive microdose semaglutide or tirzepatide program with coaching and app.
Comparing microdose plans with standard-dose prices? See cheapest semaglutide online and cheapest tirzepatide online. Eden's full compounded semaglutide program is $99/month all-in (Eden website, October 2026), which is less than any microdose plan above.
A microdose plan is still a prescription program, so ask the same questions you'd ask any provider, plus a few specific to low doses.
It may make sense if you couldn't tolerate standard escalation and your prescriber agrees a lower dose is reasonable, or you've hit your goal and want a supervised step-down rather than an abrupt stop.
It's probably the wrong choice if your main goal is maximum weight loss. The trial results that make GLP-1s compelling came from full doses. It's also a poor fit if you're not comfortable measuring small syringe volumes precisely, or if you're choosing it purely on price. A full-dose compounded program can cost less than some microdose plans.
Skip the DIY route entirely. Adjusting your own dose without your prescriber is the kind of self-measurement the FDA ties to its dosing-error reports.
If you're unsure which path fits, the RxPickr quiz weighs your budget, medication preference, and support needs against every provider we track.
Answer 10 questions and get a personalized recommendation.
Take the free quiz →GLP-1 microdosing is a marketing label for sub-maintenance doses, not a studied treatment. It may help with tolerability and cost, but the weight-loss and longevity claims attached to it rest on full-dose data. If you try it, do it through a licensed provider, know your vial's concentration, and treat the lower price as a trade-off rather than a free upgrade.